Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.

Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Deapen D, Morrow M, Jagsi R, Katz SJ.

JAMA Oncol. 2020 Feb 6:e196400. doi: 10.1001/jamaoncol.2019.6400. [Epub ahead of print]

PMID:
32027353
2.

Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data.

Ling AY, Kurian AW, Caswell-Jin JL, Sledge GW Jr, Shah NH, Tamang SR.

JAMIA Open. 2019 Sep 18;2(4):528-537. doi: 10.1093/jamiaopen/ooz040. eCollection 2019 Dec.

3.

Reply to Residual confounding threatens the validity of observational studies on breast cancer local therapy.

Kurian AW, Canchola AJ, Gomez SL.

Cancer. 2020 Jan 30. doi: 10.1002/cncr.32743. [Epub ahead of print] No abstract available.

PMID:
31999833
4.

Magnitude of reduction in risk of second contralateral breast cancer with bilateral mastectomy in patients with breast cancer: Data from California, 1998 through 2015.

Kurian AW, Canchola AJ, Ma CS, Clarke CA, Gomez SL.

Cancer. 2020 Mar 1;126(5):958-970. doi: 10.1002/cncr.32618. Epub 2019 Nov 21.

PMID:
31750934
5.

Mutations and the Importance of Genetic Testing.

Kurian AW.

Oncology (Williston Park). 2019 Oct 28;33(10). pii: 686505.

6.

Patient-clinician interactions and disparities in breast cancer care: the equality in breast cancer care study.

Gonzales FA, Sangaramoorthy M, Dwyer LA, Shariff-Marco S, Allen AM, Kurian AW, Yang J, Langer MM, Allen L, Reeve BB, Taplin SH, Gomez SL.

J Cancer Surviv. 2019 Dec;13(6):968-980. doi: 10.1007/s11764-019-00820-7. Epub 2019 Oct 23.

PMID:
31646462
7.

Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry.

Yang Y, Shu X, Shu XO, Bolla MK, Kweon SS, Cai Q, Michailidou K, Wang Q, Dennis J, Park B, Matsuo K, Kwong A, Park SK, Wu AH, Teo SH, Iwasaki M, Choi JY, Li J, Hartman M, Shen CY, Muir K, Lophatananon A, Li B, Wen W, Gao YT, Xiang YB, Aronson KJ, Spinell JJ, Gago-Dominguez M, John EM, Kurian AW, Chang-Claude J, Chen ST, Dörk T, Evans DGR, Schmidt MK, Shin MH, Giles GG, Milne RL, Simard J, Kubo M, Kraft P, Kang D, Easton DF, Zheng W, Long J.

EBioMedicine. 2019 Oct;48:203-211. doi: 10.1016/j.ebiom.2019.09.006. Epub 2019 Oct 16.

8.

Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer.

Scott D, Friedman S, Telli ML, Kurian AW.

JCO Oncol Pract. 2020 Jan;16(1):e37-e55. doi: 10.1200/JOP.19.00221. Epub 2019 Oct 15.

PMID:
31613719
9.

Natural Language Processing Approaches to Detect the Timeline of Metastatic Recurrence of Breast Cancer.

Banerjee I, Bozkurt S, Caswell-Jin JL, Kurian AW, Rubin DL.

JCO Clin Cancer Inform. 2019 Oct;3:1-12. doi: 10.1200/CCI.19.00034.

10.

Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits?

Phillips KA, Marshall DA, Kurian AW.

Per Med. 2019 Sep;16(5):365-367. doi: 10.2217/pme-2019-0045. Epub 2019 Sep 25. No abstract available.

PMID:
31552799
11.

Chromatin Remodeling in Response to BRCA2-Crisis.

Gruber JJ, Chen J, Geller B, Jäger N, Lipchik AM, Wang G, Kurian AW, Ford JM, Snyder MP.

Cell Rep. 2019 Aug 20;28(8):2182-2193.e6. doi: 10.1016/j.celrep.2019.07.057.

12.

Genomic landscape of ductal carcinoma in situ and association with progression.

Lin CY, Vennam S, Purington N, Lin E, Varma S, Han S, Desa M, Seto T, Wang NJ, Stehr H, Troxell ML, Kurian AW, West RB.

Breast Cancer Res Treat. 2019 Nov;178(2):307-316. doi: 10.1007/s10549-019-05401-x. Epub 2019 Aug 17.

PMID:
31420779
13.

Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer.

Luhn P, Chui SY, Hsieh AF, Yi J, Mecke A, Bajaj PS, Hasnain W, Falgas A, Ton TG, Kurian AW.

J Comp Eff Res. 2019 Oct;8(14):1173-1185. doi: 10.2217/cer-2019-0077. Epub 2019 Aug 9.

PMID:
31394922
14.

Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor-Positive Breast Cancer.

Roberts MC, Kurian AW, Petkov VI.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):662-668. doi: 10.6004/jnccn.2018.7266.

PMID:
31200352
15.

Is Breast Cancer in Asian and Asian American Women a Different Disease?

Gomez SL, Yao S, Kushi LH, Kurian AW.

J Natl Cancer Inst. 2019 Dec 1;111(12):1243-1244. doi: 10.1093/jnci/djz091. No abstract available.

PMID:
31093671
16.

Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.

Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, Miller D, Penberthy LS, Katz SJ.

J Clin Oncol. 2019 May 20;37(15):1305-1315. doi: 10.1200/JCO.18.01854. Epub 2019 Apr 9.

PMID:
30964716
17.

Response to Peshkin, Isaacs, and Schwartz.

Caswell-Jin JL, Kurian AW.

J Natl Cancer Inst. 2019 Aug 1;111(8):874. doi: 10.1093/jnci/djz029. No abstract available.

PMID:
30838406
18.

Automatic inference of BI-RADS final assessment categories from narrative mammography report findings.

Banerjee I, Bozkurt S, Alkim E, Sagreiya H, Kurian AW, Rubin DL.

J Biomed Inform. 2019 Apr;92:103137. doi: 10.1016/j.jbi.2019.103137. Epub 2019 Feb 23.

PMID:
30807833
19.

Primary care provider-reported involvement in breast cancer treatment decisions.

Wallner LP, Li Y, McLeod MC, Gargaro J, Kurian AW, Jagsi R, Radhakrishnan A, Hamilton AS, Ward KC, Hawley ST, Katz SJ.

Cancer. 2019 Jun 1;125(11):1815-1822. doi: 10.1002/cncr.31998. Epub 2019 Feb 1.

PMID:
30707773
20.

Association of Germline Genetic Test Type and Results With Patient Cancer Worry After Diagnosis of Breast Cancer.

Katz SJ, Ward KC, Hamilton AS, Abrahamse P, Hawley ST, Kurian AW.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00225. Epub 2018 Dec 19.

21.

Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review.

Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, Sledge GW, Mandelblatt JS, Kurian AW.

JNCI Cancer Spectr. 2018 Nov;2(4):pky062. doi: 10.1093/jncics/pky062. Epub 2018 Dec 24.

22.

Guidelines Do Not Proscribe Surgeons Performing Genetic Testing-Reply.

Katz SJ, Morrow M, Kurian AW.

JAMA Surg. 2019 Mar 1;154(3):269-270. doi: 10.1001/jamasurg.2018.4885. No abstract available.

PMID:
30540358
23.

Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer.

Seneviratne MG, Bozkurt S, Patel MI, Seto T, Brooks JD, Blayney DW, Kurian AW, Hernandez-Boussard T.

Cancer. 2019 Mar 15;125(6):943-951. doi: 10.1002/cncr.31895. Epub 2018 Dec 4.

PMID:
30512191
24.

Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer-Reply.

Kurian AW, Katz SJ.

JAMA Oncol. 2018 Dec 1;4(12):1788. doi: 10.1001/jamaoncol.2018.4959. No abstract available.

PMID:
30383131
25.

Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer.

Mariotto AB, Zou Z, Zhang F, Howlader N, Kurian AW, Etzioni R.

Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1332-1341. doi: 10.1158/1055-9965.EPI-17-1129. Epub 2018 Oct 18.

26.

Knowledge regarding and patterns of genetic testing in patients newly diagnosed with breast cancer participating in the iCanDecide trial.

Gornick MC, Kurian AW, An LC, Fagerlin A, Jagsi R, Katz SJ, Hawley ST.

Cancer. 2018 Oct 15;124(20):4000-4009. doi: 10.1002/cncr.31731. Epub 2018 Oct 5.

27.

Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.

Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY, Kurian AW.

J Natl Cancer Inst. 2019 Jan 1;111(1):95-98. doi: 10.1093/jnci/djy147.

28.

From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing.

Trosman JR, Weldon CB, Gradishar WJ, Benson AB 3rd, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA.

Value Health. 2018 Sep;21(9):1062-1068. doi: 10.1016/j.jval.2018.06.011. Epub 2018 Aug 3.

29.

Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer.

Jagsi R, Ward KC, Abrahamse PH, Wallner LP, Kurian AW, Hamilton AS, Katz SJ, Hawley ST.

Cancer. 2018 Sep 15;124(18):3668-3676. doi: 10.1002/cncr.31532. Epub 2018 Jul 23.

30.

Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy.

Pollom EL, Qian Y, Chin AL, Dirbas FM, Asch SM, Kurian AW, Horst KC, Tsai CJ.

Int J Cancer. 2018 Dec 15;143(12):3262-3272. doi: 10.1002/ijc.31747. Epub 2018 Sep 27.

31.

Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer.

Katz SJ, Bondarenko I, Ward KC, Hamilton AS, Morrow M, Kurian AW, Hofer TP.

JAMA Surg. 2018 Oct 1;153(10):909-916. doi: 10.1001/jamasurg.2018.2001. Erratum in: JAMA Surg. 2019 Mar 1;154(3):272.

32.

Screening for founder and recurrent BRCA mutations in Hong Kong and US Chinese populations.

Kwong A, Shin VY, Ma ES, Chan CT, Ford JM, Kurian AW, Tai E.

Hong Kong Med J. 2018 Jun;24 Suppl 3(3):4-6. No abstract available.

33.

Macrophages Promote Circulating Tumor Cell-Mediated Local Recurrence following Radiotherapy in Immunosuppressed Patients.

Rafat M, Aguilera TA, Vilalta M, Bronsart LL, Soto LA, von Eyben R, Golla MA, Ahrari Y, Melemenidis S, Afghahi A, Jenkins MJ, Kurian AW, Horst KC, Giaccia AJ, Graves EE.

Cancer Res. 2018 Aug 1;78(15):4241-4252. doi: 10.1158/0008-5472.CAN-17-3623. Epub 2018 Jun 7.

34.

Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.

Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, Li Y, Hawley ST, Morrow M, Jagsi R, Katz SJ.

JAMA Oncol. 2018 Aug 1;4(8):1066-1072. doi: 10.1001/jamaoncol.2018.0644.

35.

Intratumoral Spatial Heterogeneity at Perfusion MR Imaging Predicts Recurrence-free Survival in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy.

Wu J, Cao G, Sun X, Lee J, Rubin DL, Napel S, Kurian AW, Daniel BL, Li R.

Radiology. 2018 Jul;288(1):26-35. doi: 10.1148/radiol.2018172462. Epub 2018 May 1.

36.

Measuring serum melatonin in postmenopausal women: Implications for epidemiologic studies and breast cancer studies.

Chu LW, John EM, Yang B, Kurian AW, Zia Y, Yu K, Ingles SA, Stanczyk FZ, Hsing AW.

PLoS One. 2018 Apr 11;13(4):e0195666. doi: 10.1371/journal.pone.0195666. eCollection 2018.

37.

Differences in Breast Cancer Survival by Molecular Subtypes in the United States.

Howlader N, Cronin KA, Kurian AW, Andridge R.

Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):619-626. doi: 10.1158/1055-9965.EPI-17-0627. Epub 2018 Mar 28.

38.

Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.

Afghahi A, Purington N, Han SS, Desai M, Pierson E, Mathur MB, Seto T, Thompson CA, Rigdon J, Telli ML, Badve SS, Curtis CN, West RB, Horst K, Gomez SL, Ford JM, Sledge GW, Kurian AW.

Clin Cancer Res. 2018 Jun 15;24(12):2851-2858. doi: 10.1158/1078-0432.CCR-17-1323. Epub 2018 Mar 26.

39.

Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling.

Mandelblatt JS, Near AM, Miglioretti DL, Munoz D, Sprague BL, Trentham-Dietz A, Gangnon R, Kurian AW, Weedon-Fekjaer H, Cronin KA, Plevritis SK.

Med Decis Making. 2018 Apr;38(1_suppl):9S-23S. doi: 10.1177/0272989X17700624.

40.

Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer.

Katz SJ, Ward KC, Hamilton AS, Mcleod MC, Wallner LP, Morrow M, Jagsi R, Hawley ST, Kurian AW.

J Clin Oncol. 2018 Apr 20;36(12):1218-1224. doi: 10.1200/JCO.2017.76.2369. Epub 2018 Mar 12.

41.

Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels.

Kwong A, Ho JCW, Shin VY, Kurian AW, Tai E, Esserman LJ, Weitzel JN, Lin PH, Field M, Domchek SM, Lo J, Ngan HYS, Ma ESK, Chan TL, Ford JM.

Oncotarget. 2017 Dec 20;9(8):7832-7843. doi: 10.18632/oncotarget.23471. eCollection 2018 Jan 30.

42.

Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ.

Shumway DA, McLeod CM, Morrow M, Li Y, Kurian AW, Sabolch A, Hamilton AS, Ward KC, Katz SJ, Hawley ST, Jagsi R.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1237-1245. doi: 10.1016/j.ijrobp.2018.01.020. Epub 2018 Jan 9.

PMID:
29439886
43.

Patient communication of cancer genetic test results in a diverse population.

Ricker CN, Koff RB, Qu C, Culver J, Sturgeon D, Kingham KE, Lowstuter K, Chun NM, Rowe-Teeter C, Lebensohn A, Levonian P, Partynski K, Lara-Otero K, Hong C, Petrovchich IM, Mills MA, Hartman AR, Allen B, Ladabaum U, McDonnell K, Ford JM, Gruber SB, Kurian AW, Idos GE.

Transl Behav Med. 2018 Jan 29;8(1):85-94. doi: 10.1093/tbm/ibx010.

44.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS.

JAMA. 2018 Jan 9;319(2):154-164. doi: 10.1001/jama.2017.19130. Erratum in: JAMA. 2018 Feb 20;319(7):724.

45.

Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.

Kurian AW, Bondarenko I, Jagsi R, Friese CR, McLeod MC, Hawley ST, Hamilton AS, Ward KC, Hofer TP, Katz SJ.

J Natl Cancer Inst. 2018 May 1;110(5):493-500. doi: 10.1093/jnci/djx239.

46.

Treatment decisions and employment of breast cancer patients: Results of a population-based survey.

Jagsi R, Abrahamse PH, Lee KL, Wallner LP, Janz NK, Hamilton AS, Ward KC, Morrow M, Kurian AW, Friese CR, Hawley ST, Katz SJ.

Cancer. 2017 Dec 15;123(24):4791-4799. doi: 10.1002/cncr.30959. Epub 2017 Oct 9.

47.

Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks.

Lin CY, Carneal EE, Lichtensztajn DY, Gomez SL, Clarke CA, Jensen KC, Kurian AW, Allison KH.

Am J Clin Pathol. 2017 Sep 1;148(3):199-207. doi: 10.1093/ajcp/aqx063.

48.

What Factors Influence Women's Perceptions of their Systemic Recurrence Risk after Breast Cancer Treatment?

Lee KL, Janz NK, Zikmund-Fisher BJ, Jagsi R, Wallner LP, Kurian AW, Katz SJ, Abrahamse P, Hawley ST.

Med Decis Making. 2018 Jan;38(1):95-106. doi: 10.1177/0272989X17724441. Epub 2017 Aug 17.

49.

Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.

Caswell-Jin JL, Gupta T, Hall E, Petrovchich IM, Mills MA, Kingham KE, Koff R, Chun NM, Levonian P, Lebensohn AP, Ford JM, Kurian AW.

Genet Med. 2018 Feb;20(2):234-239. doi: 10.1038/gim.2017.96. Epub 2017 Jul 27.

PMID:
28749474
50.

Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer.

Wu J, Li B, Sun X, Cao G, Rubin DL, Napel S, Ikeda DM, Kurian AW, Li R.

Radiology. 2017 Nov;285(2):401-413. doi: 10.1148/radiol.2017162823. Epub 2017 Jul 14.

Supplemental Content

Loading ...
Support Center